Navigation Links
DURECT Corporation Announces Fourth Quarter and Year End 2010 Financial Results
Date:3/2/2011

h this product represents a modest revenue opportunity for DURECT by itself, the SABER technology is the basis for our POSIDUR program currently in a pivotal Phase III clinical trial as well as for multiple on-going feasibility projects seeking to deliver proteins and peptides for periods of up to one month from a single injection.


  • Financial Guidance.  Our net cash consumption is heavily influenced by the timing and structure of new corporate collaborations, as well as the achievement of milestones under existing collaborations.  While we anticipate entering into new collaborations in 2011 and beyond, assuming no new collaborations, no milestone or royalty payments and aggressive funding of our R&D programs, many of which are in clinical development, we anticipate our net cash consumption in 2011 will be approximately $23-27 million.


  • Business Development Activities.  We have multiple programs that may potentially be partnered over the next 12-18 months.  These include TRANSDUR-Sufentanil worldwide rights, POSIDUR for Japan, ORADUR-ADHD, as well as various internal programs which we have not described publicly in detail.Earnings Conference CallA live audio webcast of a conference call to discuss 2010 results will be broadcast over the internet at 4:30 p.m. Eastern Time on March 2 and is available by accessing DURECT's homepage at www.durect.com and clicking "Investor Relations." If you are unable to participate during the live webcast, the call will be archived on DURECT's website under Audio Archive in the "Investor Relations" section.

    About DURECT CorporationDURECT is a specialty pharmaceutical compan
    '/>"/>


  • SOURCE DURECT Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related biology technology :

    1. DURECTs Collaboration With Alpharma Clears HSR Review and Is Effective
    2. DURECT Corporation Announces Third Quarter 2008 Financial Results
    3. DURECT Corporation Invites You to Join its Third Quarter 2010 Earnings Conference Call
    4. Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference
    5. Pharmos Corporation Reports 2008 Second Quarter Results
    6. China Bionanometer Industries Corporation Promotes New Product Beauty Look in China
    7. Genaera Corporation Announces Second Quarter Financial Results
    8. MannKind Corporation Reports Second Quarter Financial Results
    9. [video] David Brown, President and CEO of LifeVantage Corporation, Discusses Record Page Views on WallSt.nets 3-Minute Press Show
    10. Emerging Growth Equities, Ltd. Initiates Coverage of CombiMatrix Corporation with a BUY Rating and an $18.00 Price Target
    11. CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/4/2015)... May 4, 2015 /PRNewswire/ - Fluorinov Pharma (Fluorinov), ... the appointment of Dr. Roger J Garceau, to ... biotech companies in matters including corporate development and ... and adds significant regulatory expertise as Fluorinov transitions ... brings 30 years of pharmaceutical development experience to ...
    (Date:5/4/2015)... (PRWEB) May 04, 2015 Genedata, ... drug discovery and life science research, today announced ... the latest version of its enterprise solution for ... R&D enables more efficient discovery and development of ... to integrate and address protein optimization and developability ...
    (Date:5/4/2015)... KONG , May 4, 2015 China ... the "Company"), China,s leading provider ... processing and stem cell storage services, today announced that ... Limited ("Golden Meditech"), a Hong Kong ... Company, has entered into an agreement (the "Agreement") to ...
    (Date:5/4/2015)... --  Intrexon Corporation (NYSE: XON ) today ... after the market closes on May 11, 2015.  The ... 5:30 PM ET to discuss the results and provide ... may be accessed by dialing 1-888-346-3959 (Domestic US) and ... Call."  Participants may also access the live webcast through ...
    Breaking Biology Technology:Roger J Garceau joins Fluorinov board, adds clinical expertise to bromodomain program and oncology pipeline 2Roger J Garceau joins Fluorinov board, adds clinical expertise to bromodomain program and oncology pipeline 3Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 2Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 3Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 4China Cord Blood Corporation Receives Notice of a Transaction Regarding its 7% Senior Convertible Notes Due 2017 Held by KKR 2China Cord Blood Corporation Receives Notice of a Transaction Regarding its 7% Senior Convertible Notes Due 2017 Held by KKR 3Intrexon to Announce First Quarter 2015 Financial Results on Monday, May 11, 2015 2
    ... GLASGOW, Scotland, Sept. 3 Leading neurosurgical ... in neurosurgical,diagnostic and treatment devices, along with ... and efficient at the European,Association of Neurosurgical ... than 1,000 neurosurgeons and related medical professionals,will ...
    ... PARIS, September 2 Sanofi-aventis announced,today that ... 25 and STEEPLE,studies confirm clear net clinical ... infarction (STEMI) for Lovenox(R) vs,Unfractionnated Heparin (UFH). ... year results were presented during,hotline sessions at ...
    ... Standards and Technology (NIST) have developed two ... validate the performance of analytic instruments that ... Recent years have seen a significant increase ... analytic techniques. Researchers can detect, measure and ...
    Cached Biology Technology:Elekta Demonstrates Commitment to Stereotactic Innovation at EANS 2Elekta Demonstrates Commitment to Stereotactic Innovation at EANS 3Elekta Demonstrates Commitment to Stereotactic Innovation at EANS 4New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome 2New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome 3New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome 4New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome 5Fluorescent glass SRMs are new tool for spectroscopy 2
    (Date:3/31/2015)... , March 31, 2015  Elephant Talk Communications ... a global provider of Software Defined Network Architecture (ET ... announced total revenue of approximately $20.4 million for the ... restated $19.5 million for the year ended December 31, ... 2014, the Company had completed its multi-year transition away ...
    (Date:3/24/2015)... Mar. 24, 2015 Research and Markets ... "Global Iris Recognition Market 2015-2019" report to ... Iris Recognition market to grow at a CAGR of ... report covers the present scenario and the growth prospects ... 2015-2019. To calculate the market size, the report considers ...
    (Date:3/23/2015)... BOSTON, Mass , March 23, 2015 SoundView ... shipment of NXT-ID,s (NASDAQ: NXTD ) Wocket smart wallet. SoundView ... world user feedback on their experience with the Wocket in ... experience at CVS, Whole Foods and other retailers, making both ... Kris Tuttle also says, "If the company meets ...
    Breaking Biology News(10 mins):Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4
    ... designated FV-100, which could alleviate the suffering of millions of ... stage of clinical testing in patients. Developed and ... clinical trial with FV-100 has recently been initiated in America. ... to 10,000 times more potent than existing treatments in early ...
    ... international team of scientists has proposed a set of ... reefs from ultimate destruction. Their proposal is being ... Indonesia, where leaders of six regional governments plus Australia ... largest-ever marine reserve in world history, the Coral Triangle ...
    ... the world,s second largest fish hide out for ... online on May 7th in Current Biology , ... of the iconic species and highlights just how little ... animals, the researchers said. "While commonly sighted in ...
    Cached Biology News:Clinical trials for shingles drug take an important step forward 2Rules proposed to save the world's coral reefs 2Rules proposed to save the world's coral reefs 3Disappearing act of world's second largest fish explained 2
    ... youll be telling others after you read your ... One look at the table of contents of ... interaction will tell you immediately that this is ... your personal protein chemistry library. You will want ...
    ... This exceptionally sensitive nucleic acid gel stain has ... background in gels, making it ideal for detecting ... UV transilluminators. SYBR Green I nucleic gel ... capillary electrophoresis, real-time PCR assays and bandshift assays. ...
    Synonym: modified Grace's Insect medium...
    ... is a 12 amino acid synthetic peptide whose sequence is ... peptide is (amino to carboxy terminus): C - S(338) ... - Q - V - A - P - A(348). ... control experiments with the polyclonal antibody that reacts with this ...
    Biology Products: